FindTrial
Sign In

Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion - FluvaED

Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion - FluvaED

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-000284-28-DE
Enrollment
Unknown
Registered
2006-03-08
Start date
2006-05-31
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

erectile dysfunction due to vascular impairment

Interventions

Trade Name: Locol (Fluvastatin-Natrium) 80mg Retardtablette Product Name: Fluvastatin-Natrium, 80mg (Locol 80mg Retardtablette) Pharmaceutical Form: Prolonged-release tablet Pharmaceutical form of the

Sponsors

Universitätsklinikum des Saarlandes
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: erectile dysfunction due to vascular impairment (peak flow of penile artery =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: impaired liver function acute cardiovascular event current treatment with a statin insuline dependent diabetes mellitus or orally treated diabetes mellitus with HbA1c >=7%

Design outcomes

Primary

MeasureTime frame
Main Objective: Improvement of penile blood flow and erectile function in patients treated with fluvastatin;Secondary Objective: ;Primary end point(s): penile blood flow erectile function (questionnaire)—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026